
Telix Pharmaceuticals Ltd
ASX:TLX

Intrinsic Value
The intrinsic value of one
TLX
stock under the Base Case scenario is
22.78
AUD.
Compared to the current market price of 24.42 AUD,
Telix Pharmaceuticals Ltd
is
Overvalued by 7%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Telix Pharmaceuticals Ltd
Fundamental Analysis

Telix’s reliance on complex radiopharmaceutical manufacturing and distribution channels introduces significant logistical and cost risks, potentially limiting timely and efficient market penetration.
Telix’s portfolio of targeted radiopharmaceuticals addresses high-unmet-need oncology indications, positioning the firm for rapid market adoption if efficacy and safety data continue to be strong.

Revenue & Expenses Breakdown
Telix Pharmaceuticals Ltd
Balance Sheet Decomposition
Telix Pharmaceuticals Ltd
Current Assets | 918.6m |
Cash & Short-Term Investments | 710.3m |
Receivables | 149m |
Other Current Assets | 59.3m |
Non-Current Assets | 597.9m |
Long-Term Investments | 56.1m |
PP&E | 54.3m |
Intangibles | 416.1m |
Other Non-Current Assets | 71.3m |
Free Cash Flow Analysis
Telix Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Telix Pharmaceuticals Ltd
Revenue
|
783.2m
AUD
|
Cost of Revenue
|
-299.3m
AUD
|
Gross Profit
|
483.9m
AUD
|
Operating Expenses
|
-404m
AUD
|
Operating Income
|
79.9m
AUD
|
Other Expenses
|
-30m
AUD
|
Net Income
|
49.9m
AUD
|
TLX Profitability Score
Profitability Due Diligence
Telix Pharmaceuticals Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Score
Telix Pharmaceuticals Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
TLX Solvency Score
Solvency Due Diligence
Telix Pharmaceuticals Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Score
Telix Pharmaceuticals Ltd's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLX Price Targets Summary
Telix Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
TLX
is 33.13 AUD
with a low forecast of 25.25 AUD and a high forecast of 37.8 AUD.
Dividends
Current shareholder yield for TLX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
TLX
stock under the Base Case scenario is
22.78
AUD.
Compared to the current market price of 24.42 AUD,
Telix Pharmaceuticals Ltd
is
Overvalued by 7%.